Desmopressin, as a "designer-drug," in the treatment of overactive bladder syndrome

What Was Tested

Researchers studied Vasopressin and Desmopressin in this randomized controlled trial publication.

Who Took Part

The age groups tagged for this paper are young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Patients were included in the trial period if they had >or=4 voids in the first 8-hr of the day after rising, excluding the first morning void.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

As a double-blind Vasopressin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.

In the crossover set-up each of the participants took both Vasopressin and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Antidiuretic Agents, Deamino Arginine Vasopressin, Europe, Kidney, Quality of Life, Syndrome and Tablets.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (Neurourology and urodynamics), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.